Replies to post #73230 on Biotech Values

[bladerunner1717]

Dew,

Perhaps this is a simple-minded question (not unusual coming from me): But why, if IDX 899 is shown to be clinically superior to Sustiva, wouldn't Gilead want to strike up a deal with GSK and replace Sustiva (and BMY) in the Atripla combination?

Bladerunner

[genisi]

I can think of a reason it may increase Epzicom sales.